XOFLUZA Drug Patent Profile

Which patents cover Xofluza, and what generic alternatives are available?

Xofluza is a drug marketed by Genentech Inc and is included in two NDAs. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-six patent family members in forty-two countries.

The generic ingredient in XOFLUZA is baloxavir marboxil. Two suppliers are listed for this compound. Additional details are available on the baloxavir marboxil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xofluza

A generic version of XOFLUZA was approved as baloxavir marboxil by NORWICH on June 17^th, 2026.

Summary for XOFLUZA

International Patents:	266
US Patents:	10
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	8
Patent Applications:	525
Drug Prices:	Drug price information for XOFLUZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XOFLUZA
What excipients (inactive ingredients) are in XOFLUZA?	XOFLUZA excipients list
DailyMed Link:	XOFLUZA at DailyMed

See drug prices for XOFLUZA

Recent Clinical Trials for XOFLUZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Geneva, Switzerland	PHASE3
Swiss National Science Foundation	PHASE3
Dre Pauline Vetter	PHASE3

See all XOFLUZA clinical trials

Pharmacology for XOFLUZA

Drug Class	Polymerase Acidic Endonuclease Inhibitor
Mechanism of Action	Chelating Activity Polymerase Acidic Endonuclease Inhibitors

Paragraph IV (Patent) Challenges for XOFLUZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOFLUZA	Tablets	baloxavir marboxil	40 mg and 80 mg	210854	1	2022-10-24

US Patents and Regulatory Information for XOFLUZA

XOFLUZA is protected by twelve US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-003	Mar 18, 2021	AB	RX	Yes	Yes
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	8,927,710		Y
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-003	May 30, 2025		RX	Yes	Yes	11,261,198		Y
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-002	Oct 24, 2018	AB	RX	Yes	No	11,306,106
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-002	Oct 24, 2018	AB	RX	Yes	No
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	12,064,438		Y

EU/EMA Drug Approvals for XOFLUZA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Xofluza	baloxavir marboxil	EMEA/H/C/004974Treatment of influenzaXofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above.Post exposure prophylaxis of influenzaXofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above.Xofluza should be used in accordance with official recommendations.	Authorised	no	no	no	2021-01-07

International Patents for XOFLUZA

When does loss-of-exclusivity occur for XOFLUZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

Poland

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XOFLUZA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	104428
Australia	2016256125
Brazil	112017022550
Canada	2984130
Chile	2017002711
China	107709321

Supplementary Protection Certificates for XOFLUZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3428170	LUC00198	Luxembourg		PRODUCT NAME: BALOXAVIR MARBOXIL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1500 20210108
2620436	C02620436/01	Switzerland		PRODUCT NAME: BALOXAVIRUM MARBOXILUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67426 21.02.2020
2620436	301093	Netherlands		PRODUCT NAME: BALOXAVIR MARBOXIL, ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN ERVAN; REGISTRATION NO/DATE: EU/1/20/1500 20210108
2620436	PA2021505	Lithuania		PRODUCT NAME: BALOKSAVIRO MARBOKSILAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/20/1500 20210107
2620436	122021000017	Germany		PRODUCT NAME: BALOXAVIR MARBOXIL SOWIE SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE UND SOLVATE; REGISTRATION NO/DATE: EU/1/20/1500 20210107
2620436	CA 2021 00004	Denmark		PRODUCT NAME: BALOXAVIR MARBOXIL ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1500 20210108

Last updated: July 21, 2026

Market dynamics and financial trajectory for Xofluza (baloxavir marboxil): revenue drivers, competitive pressure, and IP-driven launch risk

What is Xofluza and how does it compete in influenza?

Xofluza (baloxavir marboxil) is an oral antiviral for influenza A and B. In the US market, it is positioned against neuraminidase inhibitors (NAIs) such as oseltamivir (Tamiflu) and zanamivir, and it competes for both outpatient acute treatment and limited prophylaxis use cases depending on guideline adoption and payer rules.

Commercial thesis that has shaped uptake

• Speed of symptom improvement vs NAIs supported early clinician adoption.
• Convenience (single-dose regimens in label contexts) reduced workflow burden relative to multi-day NAIs.
• Resistance management became a core economic variable: resistance patterns can change prescriber comfort, payer coverage, and guideline emphasis.

Key market dynamics that move sales

• Guideline and formulary placement: influenza season prescribing is heavily impacted by payer preferred drug lists and insurer prior authorization.
• Clinical confidence vs resistance: as surveillance data on resistance mutations accumulates, prescriber and payer comfort can shift.
• Season severity: annual influenza activity drives volumes more than switching. In weak seasons, any category share gain erodes quickly in absolute terms.
• Generic NAIs pricing: Tamiflu has been exposed to generic competition dynamics over time, narrowing price differentials and increasing cost-pressure on newer entrants.
• Pediatric and risk-group prescribing: uptake depends on labeling fit, weight-based pediatric logistics, and hospital/clinic treatment protocols.

---

When did Xofluza launch and how did its adoption evolve across key geographies?

Adoption pattern that typically drives revenue trajectory

• Early US uptake in the first full seasons after launch.
• Subsequent growth depends on whether payers and clinicians maintained preference while resistance monitoring and competitive intensity evolved.
• International growth tends to track local influenza burden and reimbursement rules, with additional variability from national tendering and public procurement.

Revenue sensitivity drivers

• Influenza season calendar and severity: a measure of how quickly patient volumes spike and normalize.
• Formulary access: the time it takes to convert “preferred” status into sustained prescribing.
• Institutional protocols: hospital and urgent-care pathways determine whether a single-dose antiviral is routinely stocked and used.

No additional financial trajectory metrics (quarterly sales, annual revenue, geographic breakdown) are provided here because a specific, citable financial dataset for Xofluza was not included in the prompt context.

---

How do resistance, resistance surveillance, and clinical positioning affect Xofluza’s pricing power?

Resistance is the primary non-season economic lever for baloxavir. Any measurable increase in the frequency of reduced-susceptibility isolates can weaken clinical confidence even without immediate label restrictions.

Commercial impact pathways

• Prescriber behavior: clinicians may revert toward NAIs if they perceive reduced effectiveness in local cohorts.
• Payer utilization management: insurers can tighten restrictions if real-world outcomes change.
• Guideline updates: major society recommendations can recalibrate the relative standing of baloxavir.

Litigation and brand risk are not the main variable, compliance is

Xofluza’s revenue has historically been driven more by:

• clinical and payer acceptance,
• resistance monitoring,
• and influenza activity levels, than by generic substitution risks in the initial years post-launch.

---

What patents protect Xofluza, and how do patent expirations influence long-term revenue risk?

Patent estate timing is the structural determinant of long-run brand durability. Xofluza’s economic exposure depends on whether generic entry is blocked by:

• composition of matter,
• method-of-use,
• and/or formulation/manufacturing process patents, and whether those patents remain enforceable in the key jurisdictions.

How patent expiry maps to revenue erosion

• If composition patents expire later than exclusivity windows, generic entry is delayed or limited to narrow indications/dosage forms.
• If the estate is fragmented, generics can enter in segments while the brand preserves revenue in other patient populations.

Actionable framework for exclusivity-to-entry sequencing

• Orange Book listings guide US generic launch risk by listing:
  • active ingredient and dosage form,
  • approved patents,
  • and patent expiry.
• Paragraph IV filings identify attempts to launch before patent expiry, typically driving litigation and settlement outcomes that set “entry dates” for generics.

This response cannot specify the patent numbers, assignees, expiry dates, or Paragraph IV status because the prompt provides no patent dossier or Orange Book dataset to cite.

---

What is the Orange Book status of Xofluza and are there Paragraph IV challenges?

Orange Book status is the operational map for US generic risk.

What market operators watch

• whether baloxavir patents are listed for each specific NDC/dosage form,
• the latest “expiration of patent” date,
• whether any ANDA filers have submitted Paragraph IV certifications,
• and the presence of triggered litigation under the Hatch-Waxman framework.

No Orange Book listing data is included in the prompt context, so this section is not populated with patent numbers, NDCs, or litigation events.

---

What generic entry risks exist for Xofluza and what launch scenarios are plausible?

Generic launch scenarios depend on:

• patent expiry cadence,
• whether an ANDA can carve out patents by certification type,
• and whether the brand’s settlement creates a “shared exclusivity” date that delays other entrants.

High-probability launch pathways

• Full generic once composition and key formulation/method patents expire.
• Limited carve-out generic if only certain patents are avoided, while brand retains coverage for remaining segments.
• Delayed market entry via settlement or last-in-judgment outcomes.

Financial consequence model

• Brand revenue typically drops sharply after first authorized generic launches if:
  • payers remove restrictions,
  • pricing compresses quickly,
  • and prescribers shift due to cost.

No ANDA filing or settlement dataset is provided, so launch scenario dates cannot be stated.

---

How does Xofluza compare with Tamiflu (oseltamivir) and other flu antivirals in market economics?

Relative drivers of market share

• Drug acquisition cost: generics for NAIs can reduce cost-per-course.
• Dosing convenience: single-dose advantages support differential uptake when protocols allow.
• Payer rules: copays and formulary placement determine utilization more than clinical nuance once both are accessible.

Where Xofluza can outperform

• settings that prioritize clinician time savings and rapid symptom relief,
• patient groups aligned with label language that supports baloxavir use,
• formularies where the brand retains preferred status or requires less restrictive coverage.

Where NAIs can outperform

• when payer coverage and copays heavily favor generics,
• when resistance concerns shift clinician confidence toward alternative mechanisms,
• when stocking patterns are entrenched toward NAIs.

---

What settlement agreements, licensing deals, or litigation outcomes have shaped Xofluza’s competitive landscape?

Litigation outcomes can determine:

• timing of generic entry,
• scope of authorized generic launch,
• and whether market share shifts immediately to lower-priced competitors.

What matters to revenue modeling

• settlement “trigger” date,
• which NDCs/dosage forms are covered,
• and whether non-litigated patents still block additional formulations.

No case caption, court, settlement terms, or licensing agreement details were provided in the prompt context.

---

How does FDA regulatory status and label scope affect Xofluza revenue?

Label scope changes economic utilization by expanding or narrowing:

• age indications,
• timing-from-symptom-onset requirements,
• and prophylaxis or special-use settings.

Regulatory levers that change demand

• supplemental approvals for additional populations,
• safety communications,
• resistance-related labeling updates,
• and any post-marketing requirement that influences clinician behavior.

No FDA label-history timeline or regulatory event list is included in the prompt context.

---

What financial trajectory can be concluded from publicly visible market mechanics?

Without a cited financial dataset, the only defensible conclusions are mechanism-based:

Revenue trajectory typically follows

• Influenza seasonality: quarterly pattern correlates with US and global flu burden.
• Switching pressure: generic price competition in NAIs can pressure baloxavir net pricing and access.
• Resistance-driven utilization changes: any rise in reduced-susceptibility can shift prescribing back toward NAIs and constrain payer acceptance.
• Formulary access persistence: the longer baloxavir stays preferred, the more stable the revenue base during mature competition.

No numerical revenue trendlines, CAGR, gross-to-net, or segment breakdown can be produced from the prompt context.

---

Key Takeaways

• Xofluza’s market dynamics are dominated by influenza season severity, payer formulary access, and resistance-driven clinician confidence.
• Competitive economics hinge on cost-pressure from generic NAIs and whether baloxavir retains preferred positioning.
• Long-run revenue risk is structurally tied to Xofluza patent estate durability and any US Paragraph IV litigation or settlements, but patent- and Orange-Book-level specifics are not provided in the prompt context.
• A defensible financial trajectory assessment requires a citable sales dataset; mechanism-based conclusions only support qualitative drivers here.

---

FAQs

1. Does resistance to baloxavir directly reduce Xofluza utilization during peak flu seasons?
2. How do influenza guideline updates typically change payer coverage for baloxavir versus oseltamivir?
3. What is the difference between generic substitution risk and formulary access risk for Xofluza?
4. How does patient population shift (pediatrics, high-risk adults, outpatient vs hospital) affect baloxavir demand?
5. What contract and reimbursement structures (tenders, hospital formularies, prior authorization) most influence Xofluza net revenue?

---

References

1. (No citable sources were included in the prompt context.)

DrugChatter Q&A for XOFLUZA

Xofluza current sales and peak sales of the product?
What was xofluza projected peak sales?
Xofluza price without insurance?
Does xofluza have a generic?
Xofluza cost out of pocket?